

Press Release

ProStrakan Group plc

ProStrakan announces successful conclusion of EU MRP for Rectogesic™

23 March 2006. ProStrakan Group plc, the European specialty pharmaceutical company, today announces the successful conclusion of the EU Mutual Recognition Procedure (MRP) for Rectogesic™. The procedure completed successfully shortly after the “day 90” target date of 20 March. Rectogesic™ is a 0.4% topical nitroglycerin ointment indicated for the relief of pain associated with chronic anal fissures.

The first EU launch of the product was into the UK market in May 2005. Month-on-month in-market sales demonstrate significant growth. Following the successful conclusion of the MRP process, national licences will be issued in due course in the 19 additional countries included in the MRP submission application. Launches in these other European territories will take place through H1 2007.

ProStrakan obtained the EU marketing rights to Rectogesic™ from Cellegy in December 2004 and re-negotiated the licensing and distribution agreement in November 2005 resulting in a substantial improvement in gross margin.

Commenting, Dr Wilson Totten, Chief Executive of ProStrakan, said: “We are absolutely delighted to have received a positive outcome for the MRP process in such a rapid timeframe. This allows greater certainty of launches, and gives further demonstration of the exciting opportunities within our portfolio of near-term pan-European products. Together with our expanding EU commercial infrastructure, these will provide an important near term growth driver.

“This successful outcome also further validates our skills and abilities in the drug development and registration field.”

ENDS

For more information, please contact:

ProStrakan

Wilson Totten, CEO	+ 44 (0)1896 668060
Adrian Gardner, CFO	+ 44 (0)896 668060
David Watt, Corp Comms	+ 44 (0)1896 668078

Financial Dynamics

David Yates/ Sarah MacLeod	+ 44 (0)20 7831 3113
----------------------------	----------------------

Notes to Editors

ProStrakan

ProStrakan Group plc is a rapidly growing international specialty pharmaceutical company engaged in the research, development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. The company's therapeutic focus is on bone diseases, women's health and issues relating to the ageing male. Headquartered in Scotland, the company's R&D facilities are situated in Romainville, near Paris, and in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries based in Paris, Munich and Madrid.

ProStrakan floated on the London Stock Exchange in June 2005.

www.prostrakan.com